EP1294949A4 - Human tumor necrosis factor delta and epsilon - Google Patents

Human tumor necrosis factor delta and epsilon

Info

Publication number
EP1294949A4
EP1294949A4 EP01961605A EP01961605A EP1294949A4 EP 1294949 A4 EP1294949 A4 EP 1294949A4 EP 01961605 A EP01961605 A EP 01961605A EP 01961605 A EP01961605 A EP 01961605A EP 1294949 A4 EP1294949 A4 EP 1294949A4
Authority
EP
European Patent Office
Prior art keywords
epsilon
tumor necrosis
necrosis factor
human tumor
factor delta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01961605A
Other languages
German (de)
French (fr)
Other versions
EP1294949A2 (en
Inventor
Guo-Liang Yu
Jian Ni
Reinder L Gentz
Patrick J Dillon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US21153700P priority Critical
Priority to US211537P priority
Priority to US24195200P priority
Priority to US241952P priority
Priority to US254875P priority
Priority to US25487500P priority
Priority to US27624801P priority
Priority to US276248P priority
Priority to US27797801P priority
Priority to US277978P priority
Priority to US293499P priority
Priority to US29349901P priority
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to PCT/US2001/019026 priority patent/WO2001096528A2/en
Publication of EP1294949A2 publication Critical patent/EP1294949A2/en
Publication of EP1294949A4 publication Critical patent/EP1294949A4/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
EP01961605A 2000-06-15 2001-06-14 Human tumor necrosis factor delta and epsilon Withdrawn EP1294949A4 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US21153700P true 2000-06-15 2000-06-15
US211537P 2000-06-15
US24195200P true 2000-10-23 2000-10-23
US241952P 2000-10-23
US25487500P true 2000-12-13 2000-12-13
US254875P 2000-12-13
US27624801P true 2001-03-16 2001-03-16
US276248P 2001-03-16
US27797801P true 2001-03-23 2001-03-23
US277978P 2001-03-23
US29349901P true 2001-05-25 2001-05-25
US293499P 2001-05-25
PCT/US2001/019026 WO2001096528A2 (en) 2000-06-15 2001-06-14 Human tumor necrosis factor delta and epsilon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10011219A EP2431054A3 (en) 2000-06-15 2001-06-14 Human tumor necrosis factor delta and epsilon

Publications (2)

Publication Number Publication Date
EP1294949A2 EP1294949A2 (en) 2003-03-26
EP1294949A4 true EP1294949A4 (en) 2004-08-25

Family

ID=27559037

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01961605A Withdrawn EP1294949A4 (en) 2000-06-15 2001-06-14 Human tumor necrosis factor delta and epsilon
EP10011219A Withdrawn EP2431054A3 (en) 2000-06-15 2001-06-14 Human tumor necrosis factor delta and epsilon

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10011219A Withdrawn EP2431054A3 (en) 2000-06-15 2001-06-14 Human tumor necrosis factor delta and epsilon

Country Status (4)

Country Link
EP (2) EP1294949A4 (en)
AU (1) AU8285601A (en)
CA (1) CA2413160A1 (en)
WO (1) WO2001096528A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
PT2281843T (en) 2000-06-16 2017-01-02 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
AU8830101A (en) 2000-08-18 2002-03-04 Human Genome Sciences Inc Binding polypeptides and methods based thereon
EP2332563A3 (en) 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
EP2403528B1 (en) 2009-03-02 2016-04-20 Aduro Biotech Holdings, Europe B.V. Antibodies against a proliferating inducing ligand (april)
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
WO1999000518A1 (en) * 1997-06-26 1999-01-07 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
EP0911633A1 (en) * 1997-10-08 1999-04-28 Smithkline Beecham Corporation A method of identifying agonists and antagonists for tumor necrosis related receptors TR1, TR3 and TR5
WO1999028462A2 (en) * 1997-12-03 1999-06-10 Genentech, Inc. Polypeptides and nucleic acids encoding the same
WO1999050416A1 (en) * 1997-09-30 1999-10-07 Pharmacia & Upjohn Company Tnf-related death ligand
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
EP0052322B1 (en) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (en) 1982-01-06 1983-07-13 Nec Corp Data processor
EP0088046B1 (en) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipids in the aqueous phase
DE3218121A1 (en) 1982-05-14 1983-11-17 Leskovar Peter Dr Ing Pharmaceutical compositions for tumour treatment
EP0102324A3 (en) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipids and surfactants in an aqueous medium
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (en) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Means and product for the diagnosis and therapy of tumors and for the treatment of weaknesses of the cellular and humoral immune defense
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
JPH0373280B2 (en) 1984-08-15 1991-11-21 Shingijutsu Kaihatsu Jigyodan
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
WO1987001130A1 (en) 1985-08-15 1987-02-26 Stauffer Chemical Company Tryptophan producing microorganism
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
DE3689123T2 (en) 1985-11-01 1994-03-03 Xoma Corp Modular unit of antibody genes, antibodies prepared therefrom and use.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド Denaturation antibody, or improvements relating modified antibody
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3852823D1 (en) 1987-09-11 1995-03-02 Whitehead Biomedical Inst Transduktionsveränderte fibroblasts and their application.
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
AT120454T (en) 1988-06-14 1995-04-15 Cetus Oncology Corp Coupling agents and hindered, with disulfide-bound conjugate of it.
HU219485B (en) 1988-06-24 2001-04-28 Dow Chemical Co. A method of 1,4,7,10-tetraazacyclododecane derivatives, complexes thereof, and salts with antibody conjugates, and pharmaceutical compositions containing them and the preparation of diagnostic compositions comprising the complexes and conjugates
ZA8904792B (en) 1988-06-24 1991-04-24 Dow Chemical Co Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
KR900005995A (en) 1988-10-31 1990-05-07 우메모또 요시마사 Modified interleukin-2, and a method of producing
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
JP2989002B2 (en) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AT165516T (en) 1989-03-21 1998-05-15 Vical Inc Expression of exogenous polynucleotide sequences in vertebrate animals
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (en) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derived albumin has therapeutic function
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc Generating xenogeneic antibody
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
CA2093022C (en) 1990-10-05 2005-02-22 Michael W. Fanger Targeted immunostimulation with bispecific reagents
DE69128253T2 (en) 1990-10-29 1998-06-18 Chiron Corp Bispecific antibodies, methods for their manufacture and their uses
AT218889T (en) 1990-11-09 2002-06-15 Stephen D Gillies cytokines immunoconjugates
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech Inc A method for enrichment of protein variants with altered binding properties
DK0517895T3 (en) 1990-12-14 1997-04-07 Univ California Chains for chimeric receptor-associated signal transduction pathways
PT100379B (en) 1991-04-10 1999-01-29 Scripps Research Inst Libraries of heterodymeric receptors using fagomideos
DE69214709D1 (en) 1991-04-26 1996-11-28 Surface Active Ltd New antibodies and methods for their use
AU668870B2 (en) 1991-05-14 1996-05-23 Targetech, Inc Targeted delivery of genes encoding immunogenic proteins
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co., Inc. A method for reducing the immunogenicity of antibody variable domains
JPH06510278A (en) 1991-06-05 1994-11-17
AU2238292A (en) 1991-06-14 1993-01-12 Xoma Corporation Microbially-produced antibody fragments and their conjugates
ES2227512T3 (en) 1991-12-02 2005-04-01 Cambridge Antibody Technology Limited Production of antibodies against self-antigens from repertoires of antibody segments fixed in a phage.
IL99120D0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council Procedures for the production of humanized antibodies.
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa New biologically active polypeptides, their preparation and pharmaceutical compositions containing them.
US5399349A (en) 1992-02-06 1995-03-21 Paunescu; Calin Treatment of acne
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
ZA9302522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
AU658072B2 (en) 1992-06-09 1995-03-30 Hoppe Ag Latch and lockset system
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AT200625T (en) 1992-10-09 2001-05-15 Advanced Tissue Sciences Inc Liver reserve cells
WO1994009137A1 (en) 1992-10-15 1994-04-28 Genentech, Inc. Antibodies against type 2 tumor necrosis factor receptor
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
JPH08503855A (en) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション Gene therapy for cystic fibrosis
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
AU705114B2 (en) 1993-10-14 1999-05-13 Immunex Corporation Fas antagonists and uses thereof
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
WO1995020401A1 (en) 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
AU2207195A (en) * 1994-04-05 1995-10-23 Board Of Regents, The University Of Texas System Modified receptors that continuously signal
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
CA2196200A1 (en) 1994-07-29 1996-02-15 Michael Joseph Browne Novel compounds
WO1996014328A1 (en) 1994-11-07 1996-05-17 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
DE69637481D1 (en) 1995-04-27 2008-05-15 Amgen Fremont Inc Dating from immunized Xenomäusen human antibodies to IL-8
WO1996034095A1 (en) 1995-04-27 1996-10-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
KR19990008335A (en) 1995-05-05 1999-01-25 로버트 에리치. 벤슨 Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein -4
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
KR20030096450A (en) 1996-03-22 2003-12-31 휴먼 게놈 사이언시즈, 인코포레이티드 Apoptosis inducing molecule ii
JP4440344B2 (en) 1996-08-16 2010-03-24 シェーリング コーポレイションSchering Corporation Mammalian cell surface antigen; Related Reagents
EP0961831B1 (en) 1996-08-16 2008-10-29 Human Genome Sciences, Inc. Human endokine alpha
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
AU4988697A (en) 1996-10-24 1998-05-15 Vion Pharmaceuticals, Inc. Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
AU731553B2 (en) 1996-10-25 2001-04-05 Human Genome Sciences, Inc. Neutrokine alpha
DE69738539D1 (en) 1996-12-03 2008-04-10 Amgen Fremont Inc Fully human antibodies bind EGFR
US5833994A (en) 1997-01-08 1998-11-10 Paracelsian, Inc. Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
BR9806954A (en) 1997-01-14 2000-03-21 Human Genome Sciences Inc Receivers 6a and 6b tumor necrosis factor
US6261801B1 (en) 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
PT1012274E (en) 1997-01-28 2007-08-14 Craig A Rosen Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
WO1998032466A1 (en) 1997-01-29 1998-07-30 Polymasc Pharmaceuticals Plc Pegylation process
CA2285040C (en) 1997-03-17 2009-01-27 Human Genome Sciences, Inc. Death domain containing receptor 5
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
JP2002514079A (en) 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド Chimeric opg polypeptide
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7273598A (en) 1997-05-05 1998-11-27 Regents Of The University Of California, The Naphthols useful in antiviral methods
AU7705198A (en) 1997-05-30 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
US6071743A (en) 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
EP0988371A4 (en) 1997-06-11 2002-11-04 Human Genome Sciences Inc Human tumor necrosis factor receptor tr9
NZ503850A (en) * 1997-09-12 2002-12-20 Apotech S April - a novel protein with growth effects
DE19747622A1 (en) 1997-10-28 1999-04-29 Gruenzweig & Hartmann Insulating board with electromagnetic screen for use in building
ES2303358T3 (en) 1997-11-03 2008-08-01 Georgetown University Medical Center VEGI, an inhibitor of angiogenesis and tumor growth.
WO1999035170A2 (en) * 1998-01-05 1999-07-15 Genentech, Inc. Compositions and methods for the treatment of tumor
DE19813802A1 (en) 1998-03-27 1999-11-11 Retro Tech Gmbh Anti-viral activity of propolis by inhibition of viral nucleic acid polymerases
US6251868B1 (en) 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
AU4716299A (en) 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033902A1 (en) * 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
WO1999000518A1 (en) * 1997-06-26 1999-01-07 Abbott Laboratories Member of the tnf family useful for treatment and diagnosis of disease
WO1999050416A1 (en) * 1997-09-30 1999-10-07 Pharmacia & Upjohn Company Tnf-related death ligand
EP0911633A1 (en) * 1997-10-08 1999-04-28 Smithkline Beecham Corporation A method of identifying agonists and antagonists for tumor necrosis related receptors TR1, TR3 and TR5
WO1999028462A2 (en) * 1997-12-03 1999-06-10 Genentech, Inc. Polypeptides and nucleic acids encoding the same

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ARMITAGE R J: "TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBERS AND THEIR LIGANDS", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, XX, vol. 6, no. 3, 1994, pages 407 - 413, XP000917867, ISSN: 0952-7915 *
BUELOW VON G-U ET AL: "NF-AT ACTIVATION INDUCED BY A CAML-INTERACTING MEMBER OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 278, no. 5335, 3 October 1997 (1997-10-03), pages 138 - 141, XP002072292, ISSN: 0036-8075 *
DATABASE EMBL [online] 25 September 1998 (1998-09-25), HAHNE AT AL.: "Homo sapiens proliferation inducing ligand APRIL mRNA, complete cds", XP002285266, retrieved from EMBL Database accession no. AF046888 *
DATABASE GENEBANK [online] 19 September 2000 (2000-09-19), KELLY ET AL: "Tumor necrosis factor-related death ligand-1alpha [Homo sapiens]", XP002285267, retrieved from GENEBANK Database accession no. AAF59828 *
DATABASE GENEBANK [online] 19 September 2000 (2000-09-19), KELLY ET AL: "Tumor necrosis factor-related death ligand-1beta [Homo sapiens]", XP002285268, retrieved from GENEBANK Database accession no. AAF59829 *
GRUSS H-J AND DOWER S K: "Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 85, no. 12, 15 June 1995 (1995-06-15), pages 3378 - 3404, XP002094502, ISSN: 0006-4971 *
HAHNE M ET AL: "APRIL, a new ligand of the tumor necrosis factor family, Stimulates tumor cell growth", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 188, 21 September 1998 (1998-09-21), pages 1185 - 1190, XP002093077, ISSN: 0022-1007 *
KELLY KIMBERLY ET AL: "APRIL/TRDL-1, a tumor necrosis factor-like ligand, stimulates cell death", CANCER RESEARCH, vol. 60, no. 4, 15 February 2000 (2000-02-15), pages 1021 - 1027, XP002285265, ISSN: 0008-5472 *
See also references of WO0196528A3 *
SMITH C A ET AL: "THE TNF RECEPTOR SUPERFAMILY OF CELLULAR AND VIRAL PROTEINS: ACTIVATION, COSTIMULATION, AND DEATH", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 76, 25 March 1994 (1994-03-25), pages 959 - 962, XP002029050, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
EP2431054A3 (en) 2013-03-06
CA2413160A1 (en) 2001-12-20
WO2001096528A2 (en) 2001-12-20
AU8285601A (en) 2001-12-24
EP2431054A2 (en) 2012-03-21
EP1294949A2 (en) 2003-03-26
WO2001096528A3 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
TWI304407B (en) Superabsorbents, preparation thereof and use thereof
AU2001276160B2 (en) Probiotic recolonisation therapy
TWI298064B (en) 2-amimopyridine and the medical use of the same
AU7174901A (en) Bone preparation instruments and methods
AU4790501A (en) 2-alkylidene-19-nor-vitamin d compounds and their therapeutic uses
IN215218B (en) Substituted dihydro 3-halo-1H-pyrazole-5-carboxylates their preparation and use
ZA200209638B (en) Compositions and methods for the treatment of cancer.
AU2002258990A1 (en) Improvements in ablation therapy
AU2002329826A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EP1296699A4 (en) Therapeutic agents - iii
PL369867A1 (en) Bicyclic oxopyridine and oxopyrimidine derivatives
AU8038700A (en) Implants and methods for snoring treatment
IL157946D0 (en) Combination therapy
AU2001287550A1 (en) Human coagulation factor VII variants
AU8175801A (en) Biocompatible materials
HRP20060251B1 (en) Substituted oxasolidinones and their use
PL352714A1 (en) Diaminothiazoles and their use for inhibiting protein kinases
MXPA03001969A (en) 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications.
AU5462401A (en) Human coagulation factor vii variants
HU0301246A3 (en) Human coagulation factor vii variants
GB0116247D0 (en) Surgical techniques and devices
AU726486C (en) Human tumor necrosis factor delta and epsilon
AU2002352903A8 (en) Mesoporous materials and methods
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
AU7547701A (en) Magnetic array implant and prosthesis

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 20030115

AK Designated contracting states:

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent to

Countries concerned: ALLTLVMKROSI

RIN1 Inventor (correction)

Inventor name: YU, GUO-LIANG

Inventor name: GENTZ, REINDER, L.

Inventor name: DILLON, PATRICK, J.

Inventor name: NI, JIAN

RIC1 Classification (correction)

Ipc: 7A 61K 38/00 A

Ipc: 7C 07K 14/715 B

Ipc: 7C 07K 14/525 B

A4 Despatch of supplementary search report

Effective date: 20040712

17Q First examination report

Effective date: 20061018

RAP1 Transfer of rights of an ep published application

Owner name: HUMAN GENOME SCIENCES, INC.

18W Withdrawn

Effective date: 20130118